Regenerative Medicine
Cell and gene therapies, tissue repair and the capital, manufacturing and regulatory pathways that carry them from laboratory to clinic.
Regenerative Medicine & Biotechnology
Regenerative medicine and biotechnology sit at the centre of the longevity economy, moving treatment from the management of chronic disease toward the repair and replacement of failing tissue. Cell and gene therapies, engineered proteins and computational drug design are changing what medicine can address and what investors can underwrite. The Forum convenes the capital, science and policy required to carry these therapies from laboratory to clinic at scale.
The Constraint Has Moved to Manufacturing
For a century medicine has largely treated symptoms and slowed decline. A newer generation of therapeutics aims at the underlying biology of ageing tissue: replacing lost cells, correcting genetic defects and restoring organ function. Thousands of cell and gene therapy trials are now under way worldwide and a growing number of such products hold regulatory approval, but the limiting factors sit downstream in manufacturing, reimbursement and scale. The investment question has shifted from whether these therapies work to how they reach patients affordably.
Key Thematic Areas
- Cell therapies and engineered immune cells.
- Gene therapy, gene editing and delivery systems.
- Tissue engineering, organ repair and biofabrication.
- Computational protein design and molecular engineering.
- Biomanufacturing, supply chain and cost of goods.
- Clinical translation, trial design and regulatory science.
Programme & Discussion Formats
- Deal Room – curated meetings where out-licensing, co-development and financing terms are opened.
- Scientific Plenaries – principal investigators and clinical leaders setting out where the evidence stands.
- Translation Clinics – working sessions on regulatory pathways, trial design and the route to approval.
- Financing Roundtables – closed discussions on valuation, risk sharing and long development cycles.
- Signature Report – contributions to the Forum's annual signature report on pipelines and capital flows.
Relevant Perspectives
- Biotechnology founders and chief scientific officers.
- Pharmaceutical business development and licensing teams.
- Contract development and manufacturing organisations.
- Specialist life sciences funds and royalty financiers.
- Regulators and health technology assessment bodies.
- Translational researchers and clinical trial investigators.
The Future of Regenerative Medicine Investment
- Platform Economics – capital moving toward editing tools, delivery systems and multi-programme platforms.
- Manufacturing Capacity – automated, scalable production becoming as decisive as the underlying science.
- Broader Indications – therapies proven in rare disease extending toward the common conditions of later life.
- Outcome-Based Payment – instalment and results-linked agreements emerging to fund high-cost one-time therapies.
- Sovereign Capability – governments building domestic biomanufacturing and trial capacity rather than importing therapies.
Key Benefits
- Licensing Counterparties – meetings with the corporate development teams that license and co-develop assets.
- Regulatory Engagement – direct discussion with the authorities and payers who determine market access.
- Manufacturing Partners – introductions to the production and supply chain groups that decide whether a therapy scales.
- Patient Capital – investors who underwrite long development cycles rather than short exit horizons.
- Clinical Credibility – data presented to an audience of investors, regulators and prospective partners.
Global Longevity Investors Forum (GLIF). A Global Investors Forum Platform.
This is an investment-sector topic. The GLIF programme is organised around five distinct strategic tracks. Session timings and programme participation will be announced.